An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX — Meletios A Dimopoulos (2016) | RDL Network
An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, NJ Bahlis, Neil Rabin, Robert Z. Orlowski, M. Komarnicki, Kazuyuki Suzuki, Trine Lindhardt Plesner
Meletios A Dimopoulos, Darrell White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan M. Schecter, Philippe Moreau
Philippe Moreau, Donald B. White, Lotfi Benboubker, Graham P. Cook, Merav Leiba, James Morton, P. Joy Ho, K Kim, Naoki Takezako, Sonali Trivedi, Kang Wu, Tineke Casneuf, Christopher Chiu, JM Schecter, Meletios A Dimopoulos
Nizar J. Bahlis, Philippe Moreau, Hareth Nahi, Torben Plesner, Hartmut Goldschmidt, Kenshi Suzuki, Robert Z. Orlowski, Neil Rabin, Merav Leiba, Albert Oriol, Ajai Chari, Jesús F. San Miguel, Paul G. Richardson, Saad Z. Usmani, Lisa O’Rourke, Kaida Wu, Tineke Casneuf, Christopher Chiu, Xiang Qin, Meletios A Dimopoulos
Nizar J. Bahlis, Philippe Moreau, Hareth Nahi, Torben Plesner, Hartmut Goldschmidt, Kenshi Suzuki, Robert Z. Orlowski, Neil Rabin, Merav Leiba, Albert Oriol, Ajai Chari, Jesús F. San Miguel, Paul G. Richardson, Sharjeel Usmani, Lisa O’Rourke, Kang Wu, Tineke Casneuf, Christopher Chiu, Xiang Qin, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.